Paper3496540
A new member of the immunoglobulin superfamily--CTLA-4.
Brunet JF and 6 others. Nature, 1987. Cited by 1,036 papers, by iCite.
Cite this record
ConductScience Library. A new member of the immunoglobulin superfamily--CTLA-4. Papers, record 3496540. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/3496540
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics12
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Immunoglobulins | Major topic |
| Multigene Family | Major topic |
| T-Lymphocytes | Major topic |
| Amino Acid Sequence | |
| Animals | |
| Chromosome Mapping | |
| Cloning, Molecular | |
| DNA | |
| Gene Expression Regulation | |
| Mice | |
| RNA, Messenger | |
| Sequence Homology, Nucleic Acid |
Source PubMed
Cited by521
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 1,036 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42822444 | Distant lymph nodes compensate for resected tumor-draining lymph nodes during cancer immunotherapy. | Immunity | 2026 | https://conductscience.org/library/papers/42822444 | PubMed |
| 42730022 | Inhibitory immune checkpoints in preeclampsia: current landscape, mechanisms, and clinical perspectives. | Front Immunol | 2026 | https://conductscience.org/library/papers/42730022 | PubMed |
| 42680727 | Immune checkpoints and immunoregulation in metabolic diseases and cancers: pathological mechanisms and therapeutic potential. | Signal Transduct Target Ther | 2026 | https://conductscience.org/library/papers/42680727 | PubMed |
| 42568362 | Overcoming immunotherapy barriers in pediatric brain tumors: epigenetic strategies. | Front Oncol | 2026 | https://conductscience.org/library/papers/42568362 | PubMed |
| 42549409 | Association between Cytotoxic T-Lymphocyte Antigen - 4 +49A>G Variant and Reduced Risk of Recurrent Spontaneous Abortion in Indian Bengali Population: A Case-Control Study. | J Hum Reprod Sci | 2026 | https://conductscience.org/library/papers/42549409 | PubMed |
| 42428346 | New and emerging strategies for targeting cancers: Challenges and opportunities (Review). | Oncol Lett | 2026 | https://conductscience.org/library/papers/42428346 | PubMed |
| 42393377 | A guide to CAR T cell therapies: development, current status and future prospects. | Nat Rev Immunol | 2026 | https://conductscience.org/library/papers/42393377 | PubMed |
| 42327747 | Mechanisms and biomarkers of immune checkpoint inhibitor-associated myocarditis: from T cell imbalance to multicellular crosstalk. | Front Immunol | 2026 | https://conductscience.org/library/papers/42327747 | PubMed |
| 42279386 | Advances in Immune Checkpoint Inhibitors for Cancer Treatment. | Cancers (Basel) | 2026 | https://conductscience.org/library/papers/42279386 | PubMed |
| 42273361 | A homozygous CTLA-4 variant causes CTLA-4 deficiency with severe immune dysregulation. | J Hum Immun | 2026 | https://conductscience.org/library/papers/42273361 | PubMed |
| 42206056 | Unlocking the potential: current landscape and future directions of immunotherapy in gastric cancer. | Front Immunol | 2026 | https://conductscience.org/library/papers/42206056 | PubMed |
| 42162306 | Adaptive resistance in cancer immunotherapy. | Cell Mol Immunol | 2026 | https://conductscience.org/library/papers/42162306 | PubMed |
| 42158823 | Current Status and Evolution of Immunotherapy in Glioma Management. | Int J Med Sci | 2026 | https://conductscience.org/library/papers/42158823 | PubMed |
| 42064051 | Drug resistance mechanisms of immunotherapy and translational strategies for reversing resistance for hepatocellular carcinoma: from bench to bedside. | Front Immunol | 2026 | https://conductscience.org/library/papers/42064051 | PubMed |
| 41898300 | Targeting T-Cells for Cancer Treatment: Current Clinical Strategies and Challenges. | Biomedicines | 2026 | https://conductscience.org/library/papers/41898300 | PubMed |
| 41804110 | Synergizing Radiotherapy and Immune Checkpoint Inhibitors in Malignant Solid Tumours: Mechanistic Insights and Translational Frontiers. | Expert Rev Mol Med | 2026 | https://conductscience.org/library/papers/41804110 | PubMed |
| 41678466 | Influence of the tumor microenvironment on genetic mutations in thyroid carcinoma. | PLoS One | 2026 | https://conductscience.org/library/papers/41678466 | PubMed |
| 41613111 | The role of immune checkpoint molecules in cancers. | Front Immunol | 2025 | https://conductscience.org/library/papers/41613111 | PubMed |
| 41550427 | The Trojan Horse Within: Mechanisms of Immune Evasion in Breast Cancer. | Cancer Heterog Plast | 2025 | https://conductscience.org/library/papers/41550427 | PubMed |
| 41527444 | T Cell Exhaustion in Cancer Immunotherapy: Heterogeneity, Mechanisms, and Therapeutic Opportunities. | Adv Sci (Weinh) | 2026 | https://conductscience.org/library/papers/41527444 | PubMed |
Data1
The data bank entries PubMed's record names. Trial numbers are under Trials.
| Data bank | Accession |
|---|---|
| GENBANK | X05719 |
Source GENBANK
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- References
- Genes
- Drugs
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/3496540
GET https://conductscience.org/api/papers/v1/3496540/cited_by?page=2